Iterum Therapeutics shareholders reject proposal to authorize share issuance without pre-emptive rights

On August 1, 2023, Iterum Therapeutics plc (the " Company ") held an extraordinary general meeting, at which the Company’s shareholders voted on the following proposal, which is described in the Company’s definitive proxy statement, filed with the Securities and Exchange Commission on June 12, 2023. Proposal: Board Authority to Issue Ordinary Shares for Cash without First Offering Ordinary Shares to Existing Shareholders. The shareholders did not approve the grant to the board of directors of authority under Irish law to issue shares (including rights to acquire shares) for cash without first offering those shares to existing shareholders under pre-emptive rights that would otherwise apply to the issuance. This proposal required the affirmative vote of the holders of ordinary shares representing at least 75% of the votes cast on the matter to be approved. The results of the shareholders’ vote were as follows: For Against Abstain Broker Non-Votes 3,551,455 2,167,250 31,590 * * No broker